Methyl Aminolevulinate

Evidence Level: L5

Predicted Indications: 10

Methyl Aminolevulinate

Pharmacist Assessment Report

Methyl Aminolevulinate: From Its Marketed Photodynamic Use to Hereditary Hemochromatosis (Top TxGNN Prediction) and Acne (Best-Supported Candidate)

One-Sentence Summary

Methyl aminolevulinate (MAL) is a topical photosensitizer precursor that is marketed in Canada as Metvix, and the literature compiled for this report describes its approved dermatology use in photodynamic therapy (PDT). The TxGNN model’s top-ranked prediction is hereditary hemochromatosis, but it has no clinical trials and no publications behind it. The best-supported candidate among the top 10 predictions is acne, with 2 completed Phase 2 trials and 8 publications. The primary prediction is therefore a computational signal only.

Quick Overview

Item	Content
Original Indication	Not stated in the Canadian license data. Published reviews describe approved use for actinic keratosis, basal cell carcinoma and Bowen’s disease.
Predicted New Indication	Hereditary hemochromatosis (rank 1); acne is the best-supported candidate (rank 3)
TxGNN Prediction Score	0.9986 (hereditary hemochromatosis); 0.9981 (acne)
Evidence Level	L5 (hereditary hemochromatosis); L2 (acne)
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold (hereditary hemochromatosis); Hold for the top prediction, with acne as a research question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on the literature, MAL is a precursor that cells convert to protoporphyrin IX. When illuminated with red light, protoporphyrin IX generates reactive oxygen species that destroy targeted tissue. This is the basis of topical PDT.

Hereditary hemochromatosis (rank 1). MAL sits in the heme biosynthesis pathway, which may explain why the model links it to iron metabolism. However, hemochromatosis is a systemic iron overload disorder, while MAL is used topically with light activation. No evidence was found to connect the two, so this prediction should be treated as speculative. The same applies to the other metabolic predictions (Wilson disease, iron metabolism disease, drug-induced osteoporosis).

Acne (rank 3). Here the mechanism is credible. MAL is taken up by pilosebaceous units, converted to protoporphyrin IX, and activated by red light. This can damage sebaceous glands and reduce C. acnes. Reviews also note PDT benefit in acne vulgaris and other inflammatory skin diseases.

Other skin conditions. Seborrheic keratosis, common wart, psoriasis, pityriasis lichenoides and vulvar inverted follicular keratosis are all hyperproliferative or inflammatory skin conditions where PDT is mechanistically conceivable. Only common wart and psoriasis have any literature, and it is mostly indirect.

Clinical Trial Evidence

Trials for the top-ranked prediction (hereditary hemochromatosis): currently no related clinical trials registered.

Trials for acne (the best-supported candidate):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00594425	Phase 2	Completed	150	MAL-PDT cream in moderate to severe facial acne. Two-part design: open-label dose escalation, then blinded, randomized, vehicle-controlled dose-response. Results were not supplied.
NCT00673933	Phase 2	Completed	20	Blinded, randomized, intra-individual, vehicle-controlled study of MAL-PDT in acne vulgaris in patients with skin type V or VI. Results were not supplied.

No registered clinical trials were provided for the other predicted indications.

Literature Evidence

Literature for the top-ranked prediction (hereditary hemochromatosis): currently no related literature available.

Literature for acne (up to 10 most relevant):

PMID	Year	Type	Journal	Key Findings
22949035	2013	Retrospective cohort	Photochem Photobiol Sci	Real-life off-label MAL-PDT in 20 Italian dermatology departments for inflammatory and aesthetic indications, assessing effectiveness, tolerability and safety
17598868	2007	Case series	Photodermatol Photoimmunol Photomed	Seven patients with chronic folliculitis in acne-prone skin, successfully treated with MAL-PDT
38243786	2024	Review	J Cutan Med Surg	Update on approved and emerging topical PDT indications. PDT is superior or noninferior to other treatments for several conditions.
15888131	2005	Review	Photodermatol Photoimmunol Photomed	Topical PDT is established for actinic keratosis, Bowen’s disease and basal cell carcinoma, with evident benefit in acne vulgaris and other inflammatory dermatoses
28809342	2013	Review	Materials (Basel)	Dye sensitizers for PDT, including approved use in skin diseases such as acne vulgaris
20944910	2010	Review	An Bras Dermatol	PDT review. MAL is approved for actinic keratosis, basal cell carcinoma and Bowen’s disease.
23986167	2013	Review	J Drugs Dermatol	MAL/PDT has efficacy similar to ALA/PDT in actinic keratosis, SCC and Bowen’s disease, with shorter incubation time
16566733	2006	Review	J Environ Pathol Toxicol Oncol	PDT in in situ neoplasias and skin tumours, with MAL postulated as highly selective and efficacious

Several of these are general PDT reviews rather than acne-specific studies.

Other predicted indications with literature (indirect evidence only):

Common wart (Level L3): a retrospective off-label analysis (22949076), case series of recalcitrant warts (31209587, 51 patients; 37707554), and case reports (19614904). Some retrieved articles use ALA rather than MAL or address other conditions, which weakens relevance.
Psoriasis (Level L4): only general PDT reviews, a retrospective off-label analysis and a mycosis fungoides case report. None is a psoriasis-specific trial.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02323273	METVIX	Not specified	Not specified in the license data

Safety Considerations

TxGNN model contraindication signals (deep learning): the TxGNN model links methyl aminolevulinate to photoparoxysmal response and photosensitivity disease. These signals come from the TxGNN model (deep learning), not from label text, and may reflect similarities the model learned between related diseases, not biological evidence. They are consistent with its photosensitizing action.
Drug interactions: no interaction records were found.

Please refer to the package insert for full warnings and contraindications. The label text could not be obtained for this report.

Conclusion and Next Steps

Decision: Hold (for the top-ranked prediction, hereditary hemochromatosis). Acne is flagged as a research question rather than a Go decision.

Rationale:

The top prediction, hereditary hemochromatosis, rests only on a model score of 0.9986, with no trials or literature, and no evident link between a topical photosensitizer and systemic iron overload.
Acne has a credible mechanism and two completed Phase 2 trials (n=150 and n=20), but no results, no Phase 3 evidence and mostly review-level literature, so the size and direction of benefit cannot be confirmed.

To proceed, the following is needed:

Results from NCT00594425 and NCT00673933 (efficacy, dose-response, tolerability)
A Phase 3 or otherwise confirmatory study in acne
The Health Canada package insert (warnings and contraindications), the approved indications for Metvix, and its dosage form
Mechanism of action data, such as from DrugBank
A route-compatibility assessment (currently pending) to confirm topical plus light delivery fits the new indication
For common wart, MAL-specific controlled studies, since much of the existing evidence is ALA-based or case-level
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.